SATELLOS Announces Development Candidate
- SAT-3153 Designated for pre-IND Studies - TORONTO, January 03, 2023 – Satellos Bioscience Inc.
- SAT-3153 Designated for pre-IND Studies - TORONTO, January 03, 2023 – Satellos Bioscience Inc.
SATELLOS BIOSCIENCE ANNOUNCES Q3 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS TORONTO, November 23, 2022 –
-Proof of concept studies to be completed by YE- TORONTO, November 03, 2022 – Satellos
Satellos Bioscience Inc. to present preliminary preclinical proof of concept data for an additional rare
TORONTO, October 6, 2022 – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), is
SATELLOS BIOSCIENCE ANNOUNCES OTCQB LISTING IN THE UNITED STATES TORONTO, October 6, 2022 – Satellos
Satellos Bioscience Inc. Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS